Pfizer has made a new and improved bid to acquire AstraZeneca with an offer worth £69.3 billion pounds ($116.6 billion) or £55 a share – and says this is its best and final offer for the firm.

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients ...

Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...

An experimental drug stops advanced breast cancer from progressing in some people with tumors that have grown resistant to ...

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR ...

SAN ANTONIO -- Endocrine therapy after breast-conserving surgery was associated with worse health-related quality of life ...

Six products in late-stage development have the potential to launch by 2030. Credit: MargJohnsonVA via Shutterstock. · ...